MDalgorithms Inc.

mdalgorithms.com →

-53%

est. 2Y upside i

HealthcareSeries D+

Democratizing Dermatology with AI

Rank

#3361

Sector

Health Tech

Est. Liquidity

~3Y

Data Quality

Data: Low

MDalgorithms Inc. presents a moderate upside opportunity for a job seeker, driven by its strong proprietary AI and impressive growth recognized by Inc. 5000 and Deloitte Fast 500.

Last updated: March 10, 2026

Bull (25%)+100%

MDalgorithms successfully leverages its proprietary AI and large dermatological dataset to expand market share significantly, potentially through new product lines or international expansion, and resolves the product lawsuit favorably. This drives substantial revenue growth, justifying a $250M+ valuation, well above the current estimated $100M.

Base (40%)+25%

The company continues its strong growth trajectory, maintaining its competitive position in personalized skincare and haircare, but faces ongoing competition and manages the product lawsuit without major long-term impact. Revenue grows steadily, leading to an exit valuation of approximately $125M, offering moderate returns.

Bear (35%)-50%

The class action lawsuit regarding benzene in MDacne products significantly damages brand reputation and leads to substantial legal costs or settlements. Aggressive competition from well-funded incumbents like Curology erodes market share, leading to stalled growth and a down round or exit at a valuation of $50M, severely impacting common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

With $13M in total funding and an estimated current valuation of $100M, investors hold approximately 13% of the company in liquidation preferences, meaning $13M would be paid to preferred shareholders before common shareholders receive anything.

Dilution Risk

moderate

As a venture-backed company, future funding rounds are likely, which could lead to further dilution of existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for MDalgorithms Inc. equity.

View all 9 open roles at MDalgorithms Inc. →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on MDalgorithms Inc.'s data — designed to show you've done your homework.

  • 1

    “How is MDalgorithms Inc. addressing the class action lawsuit regarding benzene in MDacne products, and what measures are being taken to mitigate future product safety concerns and reputational risk?”

  • 2

    “Given the significant funding raised by competitors like Curology, what is MDalgorithms' strategy to maintain and expand its market share in the personalized dermatology space, particularly regarding customer acquisition and product innovation?”

  • 3

    “With the 'Later Stage VC' funding round in 2022 and strong growth, what is the anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition) for employees holding equity, and how is the company managing potential dilution?”

Community

Valuation Sentiment

Our model estimates -53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.